Supplement evidence

071 / 575Probiotic strain

Lactobacillus rhamnosus GG (LGG)

View my plan →

The short answer

Strain-specific evidence supports selected pediatric diarrhea and antibiotic-associated diarrhea contexts.

Evidence and scope: Conditional or population-specific
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Benefit depends on the population, formulation, baseline status, and objective; results should not be generalized.
Before deciding: Key concern: Avoid unsupervised use in severe immunocompromise, critical illness, or central venous catheters.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meal-specific digestionCommon trials use 10^9–10^10 CFU/day; indication-specific

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat/water classification is not the key factor

Fat/water solubility is not the useful decision point; preparation, fluid, timing, or strain identity matters more.

How it is commonly taken

Use the exact strain and viable count studied; storage matters.

Do not combine casually

Avoid unsupervised use in severe immunocompromise, critical illness, or central venous catheters.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

3research papers in this ledger

19unique primary studies represented

4,327unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2019

Mixed or qualifiedPMID 31025399

Lactobacillus rhamnosus GG for treating acute gastroenteritis in children: a 2019 update

LGG did not reduce stool volume but shortened diarrhea by an average 0.85 day across 15 trials. Effects varied by region and the authors emphasized high heterogeneity and methodological limitations, so the pooled estimate does not guarantee benefit in a specific setting.

Published: 2019n=4,208 participants18 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 18 randomized trials
Population: 4,208 children with acute gastroenteritis
Intervention: Lactobacillus rhamnosus GG versus placebo or no treatment
Outcome: Stool volume, diarrhea duration, and hospitalization

Open research record ↗

2018

Does not support the tested claimPMID 30462938 · NCT01773967

Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children

LGG did not reduce moderate-to-severe illness (11.8% versus 12.6%) or improve diarrhea duration, vomiting, day-care absence, or household transmission. This large null trial is already represented in the 2019 meta-analysis and is therefore not counted again.

Published: 2018Duration: 5-day treatment with follow-up through 1 month

Study design and methods

Design: Prospective, randomized, double-blind, placebo-controlled multicenter trial
Population: 971 children aged 3 months to 4 years presenting to 10 U.S. emergency departments; 943 completed
Intervention: LGG 10 billion CFU twice daily versus placebo
Outcome: Moderate-to-severe gastroenteritis, diarrhea and vomiting duration, absence, and household transmission

Funding or conflict note: Funded by the U.S. National Institutes of Health and other public or noncommercial sources.

Open research record ↗

1999

Mixed or qualifiedPMID 10545590

Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections

Diarrhea occurred in 5% with LGG and 16% with placebo; the reported absolute effect was -11 percentage points with a 95% confidence interval reaching no difference. Forty-eight of 167 invited children were lost to follow-up, limiting certainty.

Published: 1999Duration: During antibiotics with 3 months of symptom follow-upn=119 participants

Study design and methods

Design: Randomized placebo-controlled trial
Population: 119 Finnish children aged 2 weeks to 12.8 years with respiratory infections who completed follow-up
Intervention: LGG 20 billion CFU twice daily versus placebo during oral antibiotic treatment
Outcome: Antibiotic-associated diarrhea during the first 2 weeks

Open research record ↗

Unscreened discovery appendix—not evidence204 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.